1. Introduction

Context

Primary prevention of cardiovascular disease (CVD) remains a public health priority in the United Kingdom. Effective management of dyslipidaemia, particularly elevated levels of atherogenic cholesterol particles, constitutes a central pillar of this preventive strategy. Statins are the cornerstone therapy, demonstrating substantial evidence for reducing CVD morbidity and mortality.¹ However, a significant challenge arises in clinical practice with patients who experience statin intolerance, characterised by adverse effects perceived as unacceptable, which can compromise adherence or necessitate discontinuation.² While randomised controlled trials often report low rates of true statin-related adverse effects, real-world discontinuation rates can be considerably higher, potentially influenced by factors such as the nocebo effect and negative media coverage.¹ Stopping statin therapy is associated with an increased risk of major cardiovascular events, underscoring the need for clear, evidence-based pathways for managing lipid levels in statin-intolerant individuals.¹

Patient Profile

This report focuses on the specific clinical scenario of a 50-year-old patient presenting for primary CVD prevention with confirmed statin intolerance. The patient exhibits a significantly adverse lipid profile: Total Cholesterol (TC) 7.1 mmol/L, Triglycerides (TG) 3.0 mmol/L, High-Density Lipoprotein Cholesterol (HDL-C) 1.2 mmol/L, calculated non-HDL-C 5.9 mmol/L, and calculated Low-Density Lipoprotein Cholesterol (LDL-C) 4.6 mmol/L. This profile, combined with statin intolerance, necessitates a careful application of UK treatment guidelines to effectively manage CVD risk using alternative therapeutic strategies.

Report Aim

The objective of this report is to provide an expert-level overview of the current UK National Institute for Health and Care Excellence (NICE) guidelines, primarily NG238, pertaining to CVD risk assessment and lipid modification for primary prevention in the context of the described statin-intolerant patient. It will detail the recommended methods for risk assessment, the thresholds and targets for initiating and monitoring therapy, and the evidence-based use of non-statin lipid-lowering treatments available within the National Health Service (NHS).

Guideline Focus

This analysis is centred on NICE guideline NG238, “Cardiovascular disease: risk assessment and reduction, including lipid modification,” published in December 2023, which supersedes the previous guideline CG181.⁷ Relevant NICE Technology Appraisals (TAs) evaluating the clinical and cost-effectiveness of specific non-statin therapies (ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran) will also be integrated to provide a comprehensive picture of the recommended treatment pathway.

2. Cardiovascular Risk Assessment in the UK (NICE NG238)

Systematic Approach

NICE guideline NG238 advocates for a systematic strategy to identify individuals who may benefit from a formal CVD risk assessment, moving away from reliance solely on opportunistic checks.¹¹ It recommends prioritising individuals for a full formal assessment if an initial estimate, based on risk factors already documented in their primary care electronic medical records, suggests a 10-year CVD risk exceeding 10%.¹¹ This systematic identification aims to ensure that individuals at higher risk are proactively assessed.

The QRISK3 Tool

Recommendation

For the formal estimation of 10-year CVD risk in adults aged between 25 and 84 years who do not have established CVD, NICE explicitly recommends the use of the QRISK3 tool.⁶ This recommendation applies to individuals with type 2 diabetes as well, representing a shift from previous guidance which allowed other tools like Framingham or specific diabetes risk engines.¹¹ QRISK3 calculates the percentage risk of experiencing a first fatal or non-fatal myocardial infarction or stroke within the next 10 years.¹³ The tool is integrated into primary care computer systems in the UK.¹²

Factors Included

QRISK3 incorporates a wide range of variables to provide a comprehensive risk estimate. These include demographic factors (age, sex, ethnicity, postcode as a surrogate for socioeconomic deprivation), lifestyle factors (smoking status), clinical measurements (systolic blood pressure, body mass index, total cholesterol to HDL-C ratio, standard deviation of systolic blood pressure readings), and various comorbidities and clinical conditions.¹⁴ Specifically, it accounts for: type 1 or type 2 diabetes, family history of coronary heart disease in a first-degree relative under 60 years, chronic kidney disease (stages 3, 4, or 5), atrial fibrillation, current treatment for hypertension, history of migraine, rheumatoid arthritis, systemic lupus erythematosus (SLE), severe mental illness (including schizophrenia, bipolar disorder, moderate/severe depression), current use of atypical antipsychotics, regular use of oral corticosteroids, and a diagnosis or treatment for erectile dysfunction.¹¹

Lipid Input

Crucially, the specific lipid parameter required for the QRISK3 calculation itself is the ratio of Total Cholesterol to HDL Cholesterol.¹¹ While NICE recommends measuring a full lipid profile for a complete clinical picture and for guiding treatment decisions ²⁰, only this TC:HDL ratio directly informs the QRISK3 score.

Limitations & Interpretation

NICE emphasizes that clinical judgement must be applied when interpreting QRISK3 scores, as the tool may underestimate risk in certain individuals.¹¹ Groups where underestimation might occur include those taking medications known to cause dyslipidaemia (e.g., immunosuppressants, antipsychotics), people treated for HIV, individuals who have recently stopped smoking, those with severe mental illness beyond the scope captured by the tool’s variables, and individuals with triglyceride levels exceeding 4.5 mmol/L.¹¹ Furthermore, external validation studies, such as one conducted using the UK Biobank cohort, have suggested that QRISK3 may systematically overpredict 10-year CVD risk, particularly in older age groups, although discrimination was moderate overall.²¹ This reinforces the necessity of considering the score within the broader clinical context rather than as an absolute determinant. NICE also suggests considering the use of a lifetime risk tool, QRISK3-lifetime, to facilitate discussions about long-term risk and motivate lifestyle changes, particularly for individuals younger than 40 with risk factors or those with a 10-year QRISK3 score below 10%.¹¹

Interpreting Lipid Profiles (Beyond QRISK3 Input)

Full Profile Measurement

Beyond the TC:HDL ratio needed for the QRISK3 calculation, NICE NG238 recommends measuring a full lipid profile as part of the overall assessment.²⁰ This typically includes total cholesterol, HDL-C, and triglycerides, allowing for the calculation of non-HDL-C and LDL-C.²⁰ A non-fasting sample is acceptable for the initial assessment.²⁰ This comprehensive profile provides a richer understanding of the patient’s atherogenic lipoprotein burden.

Non-HDL Cholesterol

Non-HDL-C, calculated as Total Cholesterol minus HDL-C, is a crucial metric. It represents the cholesterol content of all potentially atherogenic lipoproteins, including LDL, VLDL, IDL, and lipoprotein(a). Its importance is underscored by NICE NG238 designating it as the primary treatment target for primary prevention.⁶ It is considered a particularly valuable marker when triglyceride levels are elevated, as LDL-C calculations can become less accurate under these conditions.²⁰

LDL Cholesterol

LDL-C remains recognised as a primary driver of atherosclerosis.²⁴ Although NICE NG238 uses non-HDL-C as the main target for primary prevention, LDL-C levels are still essential for baseline risk assessment, particularly in identifying potential familial hypercholesterolaemia (FH).²⁷ Furthermore, LDL-C levels are the specified target in secondary prevention settings ²⁸ and serve as key eligibility criteria and monitoring parameters for certain advanced lipid-lowering therapies like PCSK9 inhibitors and inclisiran.³⁰

Triglycerides (TG)

Triglycerides are measured as part of the full lipid profile. While moderately elevated TGs contribute to overall risk, largely through their association with atherogenic remnant particles reflected in non-HDL-C, NICE provides specific management advice primarily for significantly elevated levels (detailed in Section 6). The guideline explicitly notes that CVD risk assessment tools like QRISK3 may underestimate risk when fasting TGs are between 4.5 mmol/L and 9.9 mmol/L.²⁰

Secondary Causes

Before initiating lipid-lowering therapy or referring for specialist assessment, it is important to investigate and address potential common secondary causes of dyslipidaemia. These can include excessive alcohol consumption, poorly controlled diabetes mellitus, hypothyroidism, certain liver diseases (e.g., cholestasis), and nephrotic syndrome.²⁰

Assessing Risk for the Reference Patient

For the 50-year-old statin-intolerant patient with TC 7.1, TG 3.0, HDL 1.2, non-HDL 5.9, and LDL 4.6 mmol/L:

• Lipid Contribution: The markedly elevated non-HDL-C (5.9 mmol/L) and LDL-C (4.6 mmol/L) clearly indicate a high burden of atherogenic lipoproteins. The TC:HDL ratio for input into QRISK3 would be 7.1 / 1.2 = 5.9. The elevated TG (3.0 mmol/L) further contributes to the adverse profile, reflected in the high non-HDL-C.
• Incomplete Assessment: A definitive 10-year QRISK3 score cannot be calculated without the mandatory additional inputs: sex, ethnicity, postcode, smoking history, systolic blood pressure, BMI, and details of relevant comorbidities and family history.¹⁴
• Likely High Risk: Nevertheless, given the patient’s age (50 years) and the substantially elevated lipid levels (non-HDL-C 5.9 mmol/L, LDL-C 4.6 mmol/L), it is highly probable that their 10-year QRISK3 score will significantly exceed the 10% threshold recommended by NICE for initiating lipid-lowering therapy, even before accounting for any other potential risk factors.²⁰

Nuance in Lipid Assessment: QRISK3 Input vs. Clinical Utility

A critical point of understanding is the distinction between the lipid measure used by the QRISK3 algorithm and the lipid measures used for overall clinical assessment and treatment guidance under NICE NG238. QRISK3 utilizes only the TC:HDL ratio, likely due to the historical availability and predictive power of this metric in the large datasets used for algorithm development.¹⁴ However, clinical practice and the NG238 guideline itself place greater emphasis on the full lipid profile, particularly non-HDL-C, for comprehensive risk evaluation and as the primary target for therapeutic intervention in primary prevention.⁶

This apparent disconnect arises because non-HDL-C is now recognized as a potentially superior marker of the total burden of atherogenic lipoproteins, especially when triglycerides are elevated, a situation where LDL-C calculations can be unreliable.²⁰ NG238 reflects this updated understanding by employing QRISK3 (with its TC:HDL input) for initial risk stratification but guiding treatment intensity and assessing response based primarily on the percentage reduction achieved in non-HDL-C.²⁰ Therefore, clinicians must use the TC:HDL ratio for the QRISK3 score calculation but rely on the full lipid profile, especially non-HDL-C and triglycerides, for making informed decisions about treatment initiation, intensification, monitoring response, and identifying conditions like severe hypertriglyceridaemia or possible FH. Relying solely on the TC:HDL ratio would overlook vital information for optimal patient management.

3. Lipid Modification Thresholds and Targets (NICE NG238 – Primary Prevention)

Initiating Therapy Threshold

NICE guideline NG238 provides clear thresholds for considering lipid-lowering therapy in the context of primary CVD prevention:

• Primary Threshold: The primary indication for offering therapy (initially atorvastatin 20mg) is a 10-year QRISK3 score of 10% or greater.⁶ This threshold was lowered from 20% in previous guidance, reflecting evidence supporting earlier intervention.⁶
• Below Threshold Consideration: Importantly, the guideline explicitly states that treatment should not be automatically withheld if the QRISK3 score is below 10%.⁶ Therapy can still be considered based on an informed discussion with the patient, taking into account their preferences and any clinical concerns that risk might be underestimated by the QRISK3 tool (e.g., presence of risk factors not included in the algorithm, such as high lipoprotein(a), or a high calculated lifetime risk).¹¹ This highlights the centrality of shared decision-making.
• Age >85 Years: For individuals aged 85 years and older, who are often excluded from risk calculators, NICE recommends considering initiation of atorvastatin 20mg.²⁰ This decision requires careful clinical judgement, balancing the potential benefits against factors such as polypharmacy, comorbidities, frailty, and overall life expectancy.²⁸

Treatment Target

Once the decision to initiate therapy is made, NICE NG238 defines the target for primary prevention:

• Primary Goal: The therapeutic aim is to achieve a greater than 40% reduction in non-HDL cholesterol compared to the baseline (pre-treatment) level.⁶
• Rationale: This percentage reduction target is based on robust evidence, primarily from statin trials, demonstrating that the magnitude of reduction in atherogenic lipoproteins (LDL-C and non-HDL-C) is directly proportional to the reduction in CVD risk.¹⁶ A reduction of over 40% is typically achievable with the recommended initial therapy of atorvastatin 20mg, which is classified as a high-intensity statin.⁶
• Contrast with Secondary Prevention: This approach differs from the strategy in secondary prevention (patients with established CVD), where NICE NG238 specifies absolute targets: aiming for an LDL-C level of 2.0 mmol/L or less, or a non-HDL-C level of 2.6 mmol/L or less.²⁷ While a lower LDL-C target (e.g., <1.8 mmol/L) was considered for secondary prevention, it was ultimately rejected based on cost-effectiveness analyses and potential workload implications.⁶ For primary prevention, however, an absolute target was not set in NG238.

Reference Patient Context

For the 50-year-old statin-intolerant patient with a baseline non-HDL-C of 5.9 mmol/L, lipid-lowering therapy is clearly indicated based on their likely high QRISK3 score and markedly elevated lipid levels. The primary therapeutic goal, according to NICE NG238, would be to reduce their non-HDL-C by more than 40%, aiming for a level below 3.54 mmol/L (calculated as 5.9 mmol/L * [1 – 0.40]).

Rationale for Percentage Reduction Target in Primary Prevention

The adoption of a percentage reduction target (>40% non-HDL-C) rather than an absolute level for primary prevention in NICE NG238 reflects several considerations. Firstly, the primary prevention population is inherently more heterogeneous in terms of baseline cardiovascular risk and lipid levels compared to the secondary prevention cohort. Secondly, extensive clinical trial evidence, particularly from statin studies, has established a strong log-linear relationship between the proportional reduction in LDL-C (and by extension, non-HDL-C) and the relative reduction in major vascular events.¹⁶ A >40% reduction aligns with the expected efficacy of moderate-to-high intensity statin therapy, the recommended first-line approach.⁶ Thirdly, setting a single absolute target for all primary prevention patients could risk overtreatment in individuals at the lower end of the risk spectrum or might not represent sufficiently ambitious lowering for those starting with very high baseline levels. The percentage reduction goal ensures a significant therapeutic effect relative to the individual’s starting point and aligns well with the anticipated efficacy of the initial recommended treatment (atorvastatin 20mg). This approach simplifies the target across a diverse population while still necessitating baseline and follow-up lipid measurements to confirm that an adequate therapeutic response has been achieved.

4. Navigating Statin Intolerance: The NICE NG238 Pathway

Defining Statin Intolerance

Statin intolerance presents a significant clinical challenge due to its subjective nature and potential overlap with background musculoskeletal symptoms or the nocebo effect.¹

• NICE Definition: NICE defines intolerance pragmatically as “clinically significant adverse effects that represent an unacceptable risk to the patient or that may reduce compliance with therapy”.² Commonly cited adverse effects include muscle symptoms (pain, tenderness, weakness), significant gastrointestinal disturbances, and alterations in liver function tests.³
• Clinical Challenge & Nocebo Effect: While true statin-associated muscle symptoms (SAMS) are thought to be relatively uncommon in blinded trials, patient-reported intolerance leading to discontinuation is frequent in clinical practice, potentially affecting up to 75% of patients within two years in some observations.¹ Crossover trials suggest a substantial proportion (potentially up to 90%) of muscle symptoms attributed to statins may be due to the nocebo effect, where negative expectations influence symptom reporting.⁶ Clinicians need to be mindful of this and also of “statin reluctance” potentially driven by negative media portrayals.¹
• Objective Confirmation: Establishing true intolerance requires a structured approach. Formal definitions proposed by expert bodies like the National Lipid Association (NLA) or the International Lipid Expert Panel (ILEP) typically involve demonstrating an inability to tolerate at least two different statins, including one at the lowest available dose.⁴ Key criteria include the temporal relationship of symptoms to statin use (onset after initiation, resolution upon discontinuation, recurrence upon re-challenge) and the exclusion of other potential causes.⁴ NICE guidance implicitly supports such a process of trial and assessment before confirming intolerance.⁵
• Excluding Other Causes: Before attributing symptoms to a statin, it is crucial to screen for and manage modifiable risk factors and alternative causes. These include hypothyroidism, vitamin D deficiency, excessive physical exertion, potential drug interactions (e.g., involving CYP3A4 inhibitors like macrolides), excessive alcohol intake, and underlying neuromuscular disorders.⁴ NICE also recommends measuring baseline creatine kinase (CK) levels only if a person reports persistent, generalised, unexplained muscle symptoms before starting statin therapy.³⁹

Assessment and Management of Potential Intolerance

When a patient on statin therapy reports potential intolerance, particularly muscle symptoms, NICE recommends a systematic assessment:

• Symptom Evaluation: Characterise the symptoms. Typical SAMS often involve bilateral pain or weakness in large, proximal muscle groups (e.g., thighs, shoulders, calves) and may be exacerbated by exercise.¹ Assess the timing of onset relative to statin initiation or dose increase, and the severity and impact on daily life. Unilateral or joint-specific pain is less likely to be statin-related.⁴⁰
• CK Measurement: If muscle symptoms (pain, tenderness, weakness) develop while on a statin, measure CK levels.³⁹

• If CK is less than 5 times the upper limit of normal (<5x ULN), reassure the patient that their symptoms are unlikely to be directly caused by the statin and explore other potential causes.³⁹
• If CK is elevated >5x ULN, stop the statin immediately. Re-measure CK after 7 days; if it remains >5x ULN, do not restart that statin.³⁹
• If CK is significantly elevated (>10x ULN, or particularly >40-50x ULN), stop the statin and seek urgent specialist advice or inpatient assessment to evaluate for rhabdomyolysis or rarer conditions like Statin-Induced Necrotizing Autoimmune Myopathy (SINAM).¹
• De-challenge/Re-challenge Strategy: A core component of managing suspected intolerance is the process of stopping and restarting therapy.⁵

• Stop the current statin and wait for symptoms to resolve completely (e.g., allow at least 2-4 weeks symptom-free).¹ Document the time to symptom onset after initial start and time to resolution after stopping.¹
• Once symptoms have resolved, attempt a re-challenge. Options include: restarting the same statin at a lower dose; trying a different statin, potentially one with lower intensity or different solubility properties (e.g., hydrophilic statins like pravastatin or rosuvastatin may be better tolerated by some) ⁵; or considering intermittent dosing (e.g., alternate day or twice weekly, particularly with long half-life statins like atorvastatin or rosuvastatin, although outcome data for this is limited).³⁶
• If the lower dose or alternative statin is tolerated, gradually titrate the dose upwards as needed and tolerated, reassessing symptoms and lipids.¹

NICE Recommended Therapeutic Sequence (Primary Prevention, Confirmed Intolerance)

Once statin intolerance is reasonably confirmed (typically after failure to tolerate at least 2-3 different statins despite trying different doses or types ⁴), NICE guidance and associated Technology Appraisals outline the following sequence for primary prevention:

• Step 1: Ezetimibe Monotherapy: Offer ezetimibe 10mg daily as the first-line alternative.² NICE TA385 specifically supports ezetimibe monotherapy for primary hypercholesterolaemia (heterozygous-familial or non-familial) in adults where statins are contraindicated or not tolerated.²
• Step 2: Bempedoic Acid plus Ezetimibe: If the primary prevention target (>40% reduction in non-HDL-C from baseline) is not achieved with ezetimibe alone, NICE TA694 recommends considering the addition of bempedoic acid, typically administered as the fixed-dose combination tablet Nustendi® (180mg bempedoic acid / 10mg ezetimibe).²³ This recommendation is contingent on the commercial arrangement agreed with the NHS, which involves a price discount.⁴²
• Step 3: Injectable Therapies (PCSK9 Inhibitors / Inclisiran) – Limited Role in Primary Prevention: While highly effective at lowering LDL-C, access to injectable therapies (PCSK9 inhibitors alirocumab and evolocumab; siRNA inclisiran) for primary prevention is significantly restricted under current NICE guidance due primarily to cost-effectiveness considerations.³⁰

• PCSK9 Inhibitors (Alirocumab/Evolocumab): NICE TAs 393 and 394 generally do not recommend these agents for primary prevention in patients with non-familial hypercholesterolaemia or mixed dyslipidaemia, irrespective of statin tolerance status.³⁰ An exception exists for primary prevention in patients with Heterozygous Familial Hypercholesterolaemia (HeFH), where PCSK9 inhibitors are an option only if LDL-C remains persistently ≥ 5.0 mmol/L despite maximally tolerated oral therapy (including ezetimibe +/- bempedoic acid if appropriate).³⁰ Statin intolerance may contribute to patients reaching this high threshold, but it is the LDL-C level itself that determines eligibility.³⁰
• Inclisiran: NICE TA733 concluded that inclisiran was not cost-effective for primary prevention (either in HeFH or non-FH high-risk populations) based on the evidence available at the time of appraisal.⁴³ Therefore, its use in primary prevention is recommended only within the context of research studies.⁴³ Long-term cardiovascular outcome data from the ORION-4 trial are still awaited.⁶
• Implication: For the majority of statin-intolerant patients being managed for primary prevention under NICE guidelines, the therapeutic pathway effectively culminates with ezetimibe, potentially combined with bempedoic acid. Access to injectable therapies is reserved for those meeting very specific, restricted criteria (primarily severe HeFH) or those participating in clinical research. Specialist advice is recommended for patients intolerant to 3 different statins, particularly if they remain at high risk.⁵

Reference Patient Context

Applying this pathway to the 50-year-old statin-intolerant patient: following confirmation of intolerance via appropriate de-challenge/re-challenge attempts, the first step is ezetimibe 10mg daily.² The target is non-HDL-C < 3.54 mmol/L (>40% reduction from 5.9 mmol/L). If this target is not met after 2-3 months, the next NICE-recommended step is the fixed-dose combination of bempedoic acid and ezetimibe (Nustendi®).⁴² Given the patient’s very high baseline LDL-C (4.6 mmol/L) and non-HDL-C (5.9 mmol/L), it is possible that even this combination may not achieve the >40% non-HDL-C reduction goal. However, further escalation to PCSK9 inhibitors or inclisiran would generally fall outside routine NICE recommendations for primary prevention, unless the patient was diagnosed with HeFH and their LDL-C remained ≥ 5.0 mmol/L (for PCSK9i) or they were enrolled in a research study (for inclisiran).³⁰

Tension Between Guidelines and Available Therapies

A notable tension exists within the UK system regarding potent lipid-lowering therapies for primary prevention in statin-intolerant individuals. While NICE NG238 outlines the general principles of management and the >40% non-HDL-C reduction target ²⁰, the specific Technology Appraisals (TAs) for the most potent agents (PCSK9 inhibitors, inclisiran) impose significant restrictions on their use in primary prevention, primarily driven by cost-effectiveness analyses.³⁰

This situation arises because the absolute risk reduction achievable with lipid-lowering therapy is generally lower in primary prevention compared to secondary prevention populations. Consequently, expensive therapies face a higher bar to demonstrate value for money within the NHS’s willingness-to-pay thresholds.⁶ Additionally, when the TAs for bempedoic acid and inclisiran were conducted, long-term cardiovascular outcome data specifically for primary prevention populations were limited or pending, adding uncertainty to the economic models.⁶ Although subgroup data from the CLEAR Outcomes trial now show a significant benefit for bempedoic acid in primary prevention statin-intolerant patients ⁴⁸, the TAs reflect the evidence available at the time of their publication.

The practical implication is that clinicians managing high-risk primary prevention patients who are statin intolerant, like the reference case, may find that the NICE-commissioned oral therapies (ezetimibe +/- bempedoic acid) are insufficient to reach the desired >40% non-HDL-C reduction, yet the more potent injectable options are not routinely available for this indication under current guidance. This highlights a potential treatment gap for individuals who remain at substantial residual risk despite exhausting the commonly accessible pathway. It underscores the importance of accurate diagnosis (e.g., identifying potential HeFH), specialist referral for complex cases ⁵, and exploring eligibility for restricted access criteria or research participation.⁴³

5. Guideline-Recommended Non-Statin Therapies

The following sections detail the non-statin therapies recommended or considered within the NICE framework for managing primary hypercholesterolaemia/mixed dyslipidaemia, particularly in the context of statin intolerance.

(A) Ezetimibe

• Mechanism of Action: Ezetimibe selectively inhibits the absorption of dietary and biliary cholesterol from the intestine by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of enterocytes.³⁹ This reduces the delivery of cholesterol to the liver.
• NICE Position & Criteria (TA385): Ezetimibe monotherapy (10mg daily) is explicitly recommended by NICE TA385 as an option for treating primary hypercholesterolaemia (both heterozygous-familial and non-familial) in adults for whom initial statin therapy is contraindicated or who cannot tolerate statin therapy.² TA385 reviewed the earlier guidance (TA132) and concluded its recommendations remained appropriate, thereby endorsing its use in statin intolerance based on the original assessment of clinical and cost-effectiveness.² Ezetimibe is also recommended as an add-on therapy for patients on statins whose cholesterol is not adequately controlled.⁴¹
• Efficacy: As monotherapy, ezetimibe typically lowers LDL-C levels by approximately 15-20%.⁵¹ When added to ongoing statin therapy, it provides an additional LDL-C reduction of around 15-25% beyond that achieved by the statin alone.⁵² Its effects on other lipids are generally modest, with potential small reductions in triglycerides (~5%) and small increases in HDL-C (~3.5%).⁵¹ The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in post-ACS patients resulted in a further reduction in cardiovascular events compared to simvastatin alone, supporting the “lower is better” hypothesis for LDL-C.²
• Dosage: The standard dosage of ezetimibe is 10 mg taken orally once daily, with or without food.⁵¹
• Key Side Effects (SPC/MHRA): Ezetimibe is generally considered well-tolerated, with adverse event rates often comparable to placebo in trials.² Common side effects reported include gastrointestinal symptoms (abdominal pain, diarrhoea, flatulence) and fatigue.⁵⁶ When co-administered with a statin, headache and myalgia are also commonly reported.⁵⁷ Uncommon effects include cough, decreased appetite, dyspepsia, gastro-oesophageal reflux, nausea, hot flush, hypertension, arthralgia, muscle spasms, neck pain, and elevations in liver enzymes (ALT/AST) or CPK (primarily when used with a statin).⁵⁷ Post-marketing reports include rare instances of hypersensitivity reactions (rash, urticaria, angioedema, anaphylaxis), pancreatitis, hepatitis, cholelithiasis, cholecystitis, thrombocytopenia, depression, dizziness, paraesthesia, dyspnoea, and myopathy/rhabdomyolysis (the risk of myopathy/rhabdomyolysis is significantly increased when used concomitantly with a statin).⁵⁷ Patients should be advised to report unexplained muscle symptoms promptly.⁵⁷ Ezetimibe tablets contain lactose, which may be relevant for patients with hereditary galactose intolerance.⁵⁷ All suspected adverse drug reactions (ADRs) should be reported via the MHRA Yellow Card Scheme.⁵⁹
• Cost-Effectiveness: As TA385 upheld the recommendations of TA132, ezetimibe monotherapy for statin-intolerant patients with primary hypercholesterolaemia is considered cost-effective by NICE based on the analysis performed for the original appraisal.² Specific ICER details would reside within the TA132 documentation. Its status as a generic medication contributes to its favourable economic profile.

(B) Bempedoic Acid (with/without Ezetimibe)

• Mechanism of Action: Bempedoic acid is a prodrug activated in the liver to inhibit ATP Citrate Lyase (ACL), an enzyme acting earlier in the cholesterol biosynthesis pathway than HMG-CoA reductase (the target of statins).²⁵ By reducing cholesterol synthesis in the liver, it leads to upregulation of LDL receptors and increased clearance of LDL-C from the blood. Importantly, the activating enzyme is absent in skeletal muscle, potentially explaining the lower incidence of muscle-related side effects compared to statins.²⁵
• NICE Position & Criteria (TA694): NICE TA694 specifically recommends bempedoic acid with ezetimibe, available as a fixed-dose combination (Nustendi®), as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults.⁴² Crucially, for statin-intolerant patients, it is recommended only if ezetimibe monotherapy has not controlled LDL-C sufficiently.⁴² The recommendation is also contingent on the company providing the drug according to the agreed commercial arrangement (confidential discount).⁴² While bempedoic acid monotherapy (Nilemdo®) is licensed for use in statin-intolerant patients ⁴², TA694 positions the combination product as the next step after ezetimibe monotherapy in this specific scenario.
• Efficacy:

• LDL-C Reduction: Bempedoic acid monotherapy provides LDL-C lowering of approximately 21-28% in statin-intolerant individuals.²⁵ When added to existing statin therapy, the reduction is around 17-18%.²⁵ The fixed-dose combination with ezetimibe achieves a more substantial LDL-C reduction, estimated at around 38% in statin-intolerant patients.²⁵ The CLEAR Tranquility trial, comparing bempedoic acid + ezetimibe to placebo + ezetimibe, showed a placebo-corrected LDL-C reduction of 28.5% attributable to bempedoic acid.²⁵ Real-world data from the German MILOS cohort showed an average relative LDL-C reduction of 30.3% at 2 years with bempedoic acid or its FDC with ezetimibe.⁶¹
• Cardiovascular Outcomes: The CLEAR Outcomes trial, conducted in 13,970 statin-intolerant patients (primary and secondary prevention), demonstrated that bempedoic acid reduced the composite risk of major adverse cardiovascular events (MACE-4: CV death, nonfatal MI, nonfatal stroke, coronary revascularization) by 13% relative to placebo over a median follow-up of 40.6 months.²⁵ A pre-specified analysis of the primary prevention subgroup (n=4206) within CLEAR Outcomes showed a more pronounced relative risk reduction of 30% (Hazard Ratio 0.70; 95% CI 0.55-0.89) for the primary endpoint.⁴⁸ Furthermore, analyses applying the Cholesterol Treatment Trialists’ (CTT) methodology found that the cardiovascular risk reduction per 1 mmol/L lowering of LDL-C with bempedoic acid was comparable to that observed with statins.⁶³ Bempedoic acid also reduces levels of high-sensitivity C-reactive protein (hsCRP).⁶⁵

• Dosage: Bempedoic acid is administered as 180 mg orally once daily.⁶² The fixed-dose combination tablet (Nustendi®) contains 180 mg of bempedoic acid and 10 mg of ezetimibe, taken once daily.⁶⁹
• Key Side Effects (SPC/MHRA): Common adverse effects include hyperuricaemia (reported in TA694 population 2a/2b analysis ⁴², can precipitate gout, particularly in those with a prior history), anaemia, decreased haemoglobin, cough, gastrointestinal symptoms (constipation, diarrhoea, abdominal pain, nausea), back pain, muscle spasms, pain in extremities, arthralgia, fatigue, and elevations in liver enzymes or blood creatinine.⁶² Tendon rupture has been reported, although rarely (approx. 0.5% in trials) ⁷¹; risk factors include age over 60, concomitant use of corticosteroids or fluoroquinolones, renal failure, and pre-existing tendon disorders.⁷¹ Patients should be advised to report symptoms suggestive of tendon injury immediately.⁷² Bempedoic acid is contraindicated during pregnancy and breastfeeding.⁶² Concomitant use with simvastatin >40 mg daily is contraindicated due to increased risk of myopathy ⁶²; caution is also advised with pravastatin >40 mg daily.⁷¹ Interactions with cyclosporine (monitor levels) and bile acid sequestrants (dosing separation required due to ezetimibe component) are noted.⁷⁰ Monitoring of uric acid levels is recommended, especially in patients with a history of gout.⁷²
• Cost-Effectiveness (TA694): Bempedoic acid with ezetimibe was considered cost-effective by NICE for statin-intolerant patients whose LDL-C is not adequately controlled by ezetimibe alone, provided the commercial discount is applied.⁴² The ICER was below £20,000 per QALY gained compared to ezetimibe alone in patients not eligible for PCSK9 inhibitors. Compared to PCSK9 inhibitors (in the subgroup eligible for them), it resulted in cost savings but fewer QALYs gained (ICER >£30,000 saved per QALY lost), which was still deemed acceptable.⁴²

(C) PCSK9 Inhibitors (Alirocumab/Evolocumab)

• Mechanism of Action: Alirocumab and evolocumab are fully human monoclonal antibodies that bind to circulating proprotein convertase subtilisin/kexin type 9 (PCSK9). This prevents PCSK9 from binding to LDL receptors on hepatocytes, thereby inhibiting PCSK9-mediated degradation of these receptors. The resulting increase in LDL receptor density on the liver cell surface leads to enhanced clearance of LDL-C from the circulation.²⁶
• NICE Position & Criteria (TA393/TA394 – Primary Prevention Context): For primary prevention, the use of alirocumab (TA393) and evolocumab (TA394) is highly restricted:

• They are generally not recommended for primary prevention in individuals with non-familial hypercholesterolaemia or mixed dyslipidaemia, regardless of their statin tolerance status or lipid levels.³⁰
• The only primary prevention indication where they are recommended as an option is for patients with Heterozygous Familial Hypercholesterolaemia (HeFH), and only if their LDL-C concentration remains persistently ≥ 5.0 mmol/L despite maximally tolerated lipid-lowering therapy (which would include statins if tolerated, ezetimibe, and potentially bempedoic acid).³⁰
• For patients with established CVD (secondary prevention), lower LDL-C thresholds apply for eligibility (e.g., ≥3.5 mmol/L or ≥4.0 mmol/L depending on risk category and FH status).³⁰
• While statin intolerance might lead to patients having higher baseline LDL-C levels, potentially meeting these thresholds, intolerance itself is not an independent criterion for initiating PCSK9 inhibitors under NICE TAs; the specified LDL-C thresholds must be met.³⁰ Initiation typically requires specialist assessment.³⁰ Recommendations are contingent on the patient access scheme discounts agreed with the NHS.³⁰

• Efficacy: PCSK9 inhibitors are highly effective, providing substantial additional LDL-C reduction, typically in the range of 50-60%, when added to background statin therapy or used as monotherapy.²⁶ They have also been shown to lower lipoprotein(a) levels by approximately 25-30%.³⁵ Large cardiovascular outcome trials (FOURIER with evolocumab, ODYSSEY OUTCOMES with alirocumab) have demonstrated significant reductions in MACE in high-risk secondary prevention populations.³⁵
• Dosage: Alirocumab is typically administered as a 75 mg or 150 mg subcutaneous injection every 2 weeks; a 300 mg dose every 4 weeks is also licensed.⁷⁸ Evolocumab is recommended by NICE TA394 at a dosage of 140 mg subcutaneous injection every 2 weeks for these indications; the 420 mg monthly dose was not recommended due to lack of cost-effectiveness evidence for this specific use.³¹
• Key Side Effects (SPC/MHRA): PCSK9 inhibitors are generally well-tolerated.⁷⁹ The most common adverse reactions include injection site reactions (such as bruising, erythema, pain, swelling), nasopharyngitis, upper respiratory tract infection, influenza or flu-like symptoms, back pain, arthralgia, and myalgia.⁷⁹ Headache and nausea are also common.⁷⁹ Hypersensitivity reactions, including rash (common) and urticaria (uncommon), can occur.⁷⁹ Rare cases of angioedema have been reported.⁷⁹ The needle cover of the evolocumab pre-filled pen contains dry natural rubber (a derivative of latex), which may cause allergic reactions in sensitive individuals.⁷⁹ No consistent evidence of increased risk of neurocognitive adverse events or new-onset diabetes has emerged from large outcome trials.³⁵
• Cost-Effectiveness (TA393/TA394): For primary prevention, PCSK9 inhibitors were generally found not to be cost-effective by NICE, except for the specific subgroup of HeFH patients with LDL-C persistently ≥ 5.0 mmol/L.³¹ For broader primary prevention populations, the calculated ICERs were substantially above the standard NHS willingness-to-pay threshold of £20,000-£30,000 per QALY gained, even with the patient access scheme discounts factored in.³¹ The recommendations for the eligible subgroups rely heavily on these discounts.

(D) Inclisiran

• Mechanism of Action: Inclisiran is a first-in-class small interfering RNA (siRNA) therapeutic. It specifically targets the messenger RNA (mRNA) encoding for PCSK9 within hepatocytes, leading to the catalytic breakdown of this mRNA. This prevents the synthesis of PCSK9 protein, resulting in increased expression of LDL receptors on the liver cell surface and consequently, enhanced uptake and clearance of LDL-C from the circulation.³²
• NICE Position & Criteria (TA733 – Primary Prevention Context): NICE TA733 recommends inclisiran only in the context of research for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in the primary prevention setting.⁴³ This applies to both the HeFH population and the non-FH population considered at elevated risk (defined in the trials as having type 2 diabetes, HeFH, or a 10-year CVD risk ≥20% based on Framingham or equivalent).⁴³ The “only in research” recommendation stems from significant uncertainties regarding its cost-effectiveness in primary prevention and the absence of direct cardiovascular outcome data at the time of the appraisal.⁶
• In contrast, for secondary prevention (patients with established ASCVD), inclisiran is recommended as an option if LDL-C levels remain ≥2.6 mmol/L despite maximally tolerated statins (with or without ezetimibe).²⁴ Statin intolerance is encompassed within the definition of “maximally tolerated” therapy.⁸³ This secondary prevention recommendation is linked to a specific commercial agreement between the manufacturer and NHS England aimed at wide-scale implementation.²⁴

• Efficacy: Clinical trials (ORION programme) have consistently shown that inclisiran, administered twice-yearly after initial doses, reduces LDL-C levels by approximately 50% compared to placebo when added to maximally tolerated background lipid-lowering therapy.⁶ This effect is observed rapidly (within 14 days of the first dose) and is sustained over time with the 6-monthly dosing schedule.⁸⁶ Long-term extension data from ORION-8, covering up to 6.8 years of exposure, confirm the durability of LDL-C lowering and have not identified new safety signals.²⁴ Direct cardiovascular outcome data are still pending the completion of the large ORION-4 trial, expected around 2026.⁶
• Dosage: Inclisiran is administered as a 284 mg subcutaneous injection. The dosing schedule involves an initial dose, a second dose at 3 months, and subsequent doses every 6 months thereafter.³²
• Key Side Effects (SPC/MHRA): The most frequently reported adverse reaction associated with inclisiran is injection site reactions, occurring in approximately 8.2% of patients in pivotal trials.⁴⁵ These reactions typically include pain, erythema (redness), and rash at the injection site, and are generally reported as mild to moderate in severity and transient.⁴⁵ Discontinuation due to injection site reactions is rare (0.2%).⁸⁷ Other adverse events reported in trials (e.g., arthralgia, urinary tract infection, diarrhoea, bronchitis, dyspnoea, back pain) occurred at rates similar to placebo, making causality uncertain.⁹⁰ Inclisiran is not expected to have clinically significant drug-drug interactions as it is not metabolized by cytochrome P450 enzymes nor is it a substrate or inhibitor/inducer of common drug transporters.⁴⁵ Inclisiran is designated as an MHRA Black Triangle (▼) medicine, indicating it is under intensive monitoring, and healthcare professionals are requested to report all suspected adverse reactions via the Yellow Card Scheme.⁴⁵
• Cost-Effectiveness (TA733): As noted above, inclisiran was deemed not cost-effective for primary prevention by NICE based on the analysis conducted for TA733, leading to the restriction of its use to research settings for this indication.⁴³ The ICERs calculated for primary prevention populations were considered too high relative to the expected benefits in the absence of outcome data at that time. The recommendation for secondary prevention relies on the specific commercial arrangement with NHS England.²⁴

Table 1: Summary of NICE-Relevant Non-Statin Therapies for Primary Prevention in Statin Intolerance

Agent	Relevant NICE TA	NICE Position/Criteria for Statin Intolerant Primary Prevention	Typical LDL-C Reduction†	Standard UK Dose
Ezetimibe	TA385 (reviewing TA132)	Recommended as monotherapy option if statins contraindicated or not tolerated.2	~15-20% (monotherapy) 52	10 mg once daily
Bempedoic Acid + Ezetimibe (FDC)	TA694	Recommended as an option only if statins contraindicated/not tolerated AND ezetimibe alone is insufficient. Contingent on commercial arrangement.42	~38% (vs untreated baseline) 25	180mg/10mg once daily
PCSK9 Inhibitors (Alirocumab/ Evolocumab)	TA393 / TA394	Not recommended for non-FH primary prevention. Recommended only for HeFH primary prevention if LDL-C persistently ≥ 5.0 mmol/L despite max tolerated therapy. Contingent on PAS.30	~50-60% (added to statin/mono) 35	See text (SubQ inj.)
Inclisiran	TA733	Recommended only in the context of research for primary prevention (both HeFH and non-FH high risk) due to cost-effectiveness uncertainty.43	~50% (added to max tolerated LLT) 85	284 mg SubQ inj.*

† LDL-C reduction percentages are approximate and can vary based on baseline levels and background therapy.

* Initial dose, dose at 3 months, then every 6 months.

FDC = Fixed-Dose Combination; HeFH = Heterozygous Familial Hypercholesterolaemia; LLT = Lipid-Lowering Therapy; Max = Maximum; PAS = Patient Access Scheme; SubQ inj. = Subcutaneous injection.

Table 2: Key Adverse Effects of Non-Statin Therapies (Based on SPC/MHRA Information)

Agent	Common Adverse Effects (>1/100)	Clinically Significant/Serious Adverse Effects or Warnings
Ezetimibe	Abdominal pain, diarrhoea, flatulence, fatigue. When co-administered with statin: headache, myalgia.56	Rare: Hypersensitivity (rash, angioedema, anaphylaxis), pancreatitis, hepatitis, cholelithiasis, thrombocytopenia, myopathy/rhabdomyolysis (risk mainly with statin co-administration). Contains lactose.57
Bempedoic Acid (+/- Ezetimibe)	Hyperuricaemia (may precipitate gout), anaemia, cough, GI symptoms (constipation, diarrhoea, nausea, abdo pain), back pain, muscle spasms, pain in extremity, arthralgia, fatigue, increased LFTs/creatinine.62	Rare: Tendon rupture (risk factors: age>60, steroids, fluoroquinolones, renal failure, prior tendon issues). Contraindicated: Pregnancy, breastfeeding, simvastatin >40mg. Caution: Pravastatin >40mg, cyclosporine, fibrates (ezetimibe component). Monitor uric acid.62
PCSK9 Inhibitors (Alirocumab/ Evolocumab)	Injection site reactions (bruising, erythema, pain, swelling), nasopharyngitis, upper respiratory tract infection, influenza/flu-like illness, back pain, arthralgia, myalgia, headache, nausea.79	Uncommon: Urticaria. Rare: Angioedema. Hypersensitivity reactions possible. Evolocumab pre-filled pen needle cover contains latex derivative.79
Inclisiran	Injection site reactions (pain, erythema, rash) – typically mild/moderate & transient.45	MHRA Black Triangle (▼) drug – report suspected ADRs. No significant drug interactions expected. Avoid in pregnancy/breastfeeding (precautionary).45

Table 3: NICE Cost-Effectiveness Summary for Non-Statins in Primary Prevention/Statin Intolerance

Agent	Relevant NICE TA	Population (Statin Intolerant Primary Prevention)	NICE Cost-Effectiveness Conclusion	Key Rationale/Context (Simplified)
Ezetimibe	TA385 (via TA132)	Primary Hypercholesterolaemia (FH & non-FH)	Recommended (Implied cost-effective based on original TA132 analysis).2	Generic status, established use, met cost-effectiveness thresholds in original appraisal.2
Bempedoic Acid + Ezetimibe (FDC)	TA694	Primary Hypercholesterolaemia/Mixed Dyslipidaemia (where ezetimibe alone insufficient)	Recommended only if commercial arrangement (discount) applies.42 Considered cost-effective vs ezetimibe alone (if ineligible for PCSK9i) or vs PCSK9i (if eligible, cost-saving but fewer QALYs).42	ICER <£20k/QALY vs ezetimibe alone (if PCSK9i ineligible). ICER >£30k saved/QALY lost vs PCSK9i (if eligible). Relies heavily on confidential discount.42
PCSK9 Inhibitors (Alirocumab/ Evolocumab)	TA393 / TA394	Primary Hypercholesterolaemia/Mixed Dyslipidaemia (Non-FH)	Not recommended.31	ICERs generally above £20k-£30k/QALY threshold for primary prevention, even with PAS discount.31
		Primary Hypercholesterolaemia (HeFH, LDL-C < 5.0 mmol/L)	Not recommended.31	ICERs generally above £20k-£30k/QALY threshold.31
		Primary Hypercholesterolaemia (HeFH, LDL-C ≥ 5.0 mmol/L)	Recommended only if PAS discount applies.30	ICERs potentially within acceptable range (£22k-£26k/QALY for evolocumab 31; £29k-£37k/QALY for alirocumab 46, but sensitive to assumptions) only at this high LDL-C threshold and with discount.
Inclisiran	TA733	Primary Hypercholesterolaemia/Mixed Dyslipidaemia (HeFH or non-FH elevated risk)	Recommended only in the context of research.43	Considered not cost-effective based on evidence at time of appraisal. High uncertainty in ICERs (likely >£20k/QALY) and lack of outcome data contributed to decision.43

PAS = Patient Access Scheme; FDC = Fixed-Dose Combination; FH = Familial Hypercholesterolaemia; HeFH = Heterozygous FH; ICER = Incremental Cost-Effectiveness Ratio; QALY = Quality-Adjusted Life Year.

Efficacy versus Access in Primary Prevention

The sequence of therapy recommended by NICE for statin-intolerant primary prevention patients reveals a pattern where access is often inversely related to LDL-C lowering potency. Ezetimibe, offering modest LDL-C reduction (~18%), is readily accessible and cost-effective as the first step.² Bempedoic acid plus ezetimibe provides greater efficacy (~38% reduction) and demonstrated CV outcome benefits in statin-intolerant patients ⁴⁸, but its access is positioned after ezetimibe failure and relies on a commercial discount to achieve cost-effectiveness.⁴² The most potent agents, PCSK9 inhibitors and inclisiran (~50-60% LDL-C reduction) ⁷⁵, face the most significant access restrictions in primary prevention due to their higher costs failing to meet NICE’s cost-effectiveness thresholds for this population, except under very specific circumstances (severe HeFH for PCSK9i) or within research settings (inclisiran).³¹

This creates a potential clinical dilemma for patients like the reference case. With a baseline LDL-C of 4.6 mmol/L and non-HDL-C of 5.9 mmol/L, achieving the NICE primary prevention target (>40% non-HDL-C reduction, i.e., <3.54 mmol/L) or levels considered optimal by other international guidelines (e.g., ESC/EAS advocating for LDL-C <1.8 or even <1.4 mmol/L in high/very high-risk primary prevention ³⁴) might be challenging using only the NICE-commissioned oral therapies (ezetimibe +/- bempedoic acid). An ~18% reduction with ezetimibe would yield a non-HDL-C of ~4.8 mmol/L, while an approximate ~38% reduction with the combination might yield ~3.7 mmol/L – potentially falling short of the >40% target. While clinically desirable, the pathway to accessing more potent therapies is constrained by economic evaluations within the NHS framework for primary prevention. This reinforces the treatment gap identified earlier and the need for careful patient selection, specialist input, and consideration of all available options, including research participation where appropriate.

6. Managing Elevated Triglycerides (TG ≥ 2.3 mmol/L)

NICE NG238 Recommendations

NICE guideline NG238 provides specific guidance on assessing and managing elevated triglyceride levels, distinct from the primary focus on non-HDL-C or LDL-C lowering for CVD risk reduction:

• Assessment Thresholds and Actions ²⁰:

• TG 4.5–9.9 mmol/L: Clinicians should be aware that standard CVD risk assessment tools (like QRISK3) may underestimate the true cardiovascular risk in these individuals. Management should focus on optimising control of all other modifiable CVD risk factors. Specialist advice should be sought if the non-HDL cholesterol level is concomitantly very high (> 7.5 mmol/L).
• TG 10.0–20.0 mmol/L: Repeat the triglyceride measurement using a fasting blood sample (the repeat test should be done after 5 days but within 2 weeks). Thoroughly review for, and manage, potential secondary causes of hyperlipidaemia (e.g., excessive alcohol intake, poor glycaemic control in diabetes, hypothyroidism, certain medications, renal disease). If the fasting triglyceride level remains persistently above 10.0 mmol/L after addressing secondary causes, specialist advice should be sought.
• TG >20.0 mmol/L: This level indicates severe hypertriglyceridaemia, carrying a significant risk of acute pancreatitis. Urgent specialist review is required, unless the elevation is clearly attributable to excess alcohol intake or very poor glycaemic control which needs immediate management.

• Focus on Non-HDL-C: The guideline reinforces that when triglycerides are elevated, non-HDL-C is a particularly important measure of atherogenic cholesterol burden, as standard LDL-C calculations (like the Friedewald formula) become inaccurate, often underestimating LDL-C.²⁰ The primary prevention treatment target remains focused on achieving a >40% reduction in non-HDL-C.⁶
• Therapies Not Routinely Recommended for CVD Prevention: NG238 explicitly advises against the routine use of fibrates, nicotinic acid, or bile acid sequestrants for the primary or secondary prevention of CVD.⁶ Similarly, omega-3 fatty acid compounds are generally not recommended for CVD prevention, with a specific exception for icosapent ethyl, which is subject to separate NICE guidance (TA805) for patients with specific criteria (established CVD, LDL-C controlled on statin, raised fasting TGs [1.7–5.6 mmol/L], and high CVD risk) – this is outside the scope of the current patient scenario.¹⁰ Management of elevated TGs in the context of CVD prevention primarily involves addressing secondary causes, implementing lifestyle changes, and using therapies proven to lower non-HDL-C/LDL-C and reduce CVD events (i.e., statins or the recommended alternatives for intolerance).

Relevance for the Reference Patient

The reference patient has a triglyceride level of 3.0 mmol/L.

• This level is elevated compared to optimal levels (typically <1.7 mmol/L) but falls below the 4.5 mmol/L threshold where NICE mandates specific additional actions or flags significant underestimation of risk by assessment tools.²⁰
• However, the TG level of 3.0 mmol/L significantly contributes to the patient’s very high non-HDL-C level of 5.9 mmol/L (Non-HDL-C = TC – HDL-C = 7.1 – 1.2 = 5.9 mmol/L).
• Therefore, the primary therapeutic strategy remains dictated by the need to lower the overall atherogenic burden, as reflected by the high non-HDL-C, following the established NICE pathway for statin intolerance (i.e., ezetimibe, followed by bempedoic acid/ezetimibe combination if needed).²⁰
• Concurrently, addressing potential lifestyle contributors to elevated triglycerides is essential. This includes advice on diet (reducing refined carbohydrates and sugars, moderating alcohol intake), weight management, and ensuring optimal glycaemic control if the patient has diabetes.²²

Triglycerides: Marker and Contributor, Not Primary Target (in NG238)

NICE NG238’s approach reflects the understanding that while elevated triglycerides are clearly associated with increased CVD risk, much of this risk is mediated through associated atherogenic remnant lipoproteins (contained within VLDL and IDL) and their frequent co-existence with low HDL-C and small, dense LDL particles. These factors are broadly captured by the non-HDL-C measurement. The guideline provides specific management pathways for very high triglyceride levels (>10 mmol/L or especially >20 mmol/L) primarily due to the associated risk of pancreatitis, which often requires specialist input and potentially fibrate therapy.²⁰ However, for moderate elevations like the 3.0 mmol/L seen in the reference patient, the focus remains squarely on reducing non-HDL-C using evidence-based therapies known to lower LDL-C and non-HDL-C and demonstrably reduce cardiovascular events.²⁰

Evidence supporting the use of specific triglyceride-lowering therapies (like fibrates) solely for CVD risk reduction, particularly when added to effective statin therapy (or alternatives), has been inconsistent in major cardiovascular outcome trials. NICE therefore prioritises therapies with robust evidence for non-HDL-C/LDL-C lowering and event reduction (statins, ezetimibe, bempedoic acid, PCSK9i/inclisiran within their specific indications).⁶ For patients like the reference case, the elevated triglycerides serve as an important marker contributing to the high non-HDL-C and overall risk profile, reinforcing the need for effective non-HDL-C lowering via the guideline pathway and emphasizing the importance of addressing underlying lifestyle factors, rather than indicating a need for specific TG-targeting medication for CVD prevention purposes under current NICE guidance.

7. Role of Lifestyle Interventions

Alongside pharmacological therapy, lifestyle modification remains a fundamental component of CVD prevention, recommended by NICE for all individuals, irrespective of their calculated risk score or need for medication.⁶ These interventions should be discussed at the time of risk assessment and initiation of any lipid-lowering therapy.²⁹ Key recommendations from NICE NG238 include:

• Diet: Adoption of a cardioprotective dietary pattern. This involves limiting total fat intake to 30% or less of total daily energy and saturated fat intake to 7% or less of total energy.²⁹ Emphasis is placed on replacing saturated fats with mono-unsaturated fats (e.g., using olive oil or rapeseed oil and spreads based on these oils) and polyunsaturated fats.²⁹ General healthy eating advice includes reducing dietary cholesterol, increasing intake of fruits, vegetables, and whole grains, and incorporating sources of viscous fibre (5-10g/day) and plant sterols/stanols (2-3g/day), which can contribute to LDL-C reduction.³⁴ Dietary advice should be tailored to individual circumstances, comorbidities, and other ongoing treatments.²⁹
• Physical Activity: Engaging in regular physical activity is crucial. Adults should aim for at least 150 minutes of moderate-intensity aerobic activity (e.g., brisk walking, cycling) or at least 75 minutes of vigorous-intensity aerobic activity per week, or an equivalent combination.²² Muscle-strengthening activities involving major muscle groups are also recommended on two or more days a week.
• Smoking Cessation: All individuals who smoke should be strongly advised to stop and offered support and referral to smoking cessation services.⁶
• Alcohol Consumption: Alcohol intake should be moderated and kept within recommended limits, currently advised as no more than 14 units per week for both men and women in the UK, spread over several days with alcohol-free days included.⁶
• Weight Management: Maintaining a healthy body weight (typically aiming for a BMI between 20-25 kg/m²) is important. Individuals who are overweight or obese should be encouraged and supported to lose weight through dietary changes and increased physical activity.⁶ Referral to weight management services may be appropriate.³⁴

These lifestyle interventions are not merely adjuncts but are integral to managing overall cardiovascular risk. They can significantly improve lipid profiles, blood pressure, glycaemic control, and other risk factors, complementing the effects of pharmacological therapy.¹¹ NICE recommends assessing a person’s readiness and confidence to make lifestyle changes as part of the initial consultation.²⁹

8. Monitoring Lipid-Lowering Therapy

Effective management requires appropriate monitoring to assess treatment efficacy and safety.

• Baseline Assessment: Before initiating any lipid-lowering therapy, a baseline assessment is necessary. This includes a full, non-fasting lipid profile (TC, HDL-C, TG, calculated non-HDL-C and LDL-C).²⁰ Baseline liver function tests (LFTs, specifically ALT or AST) should also be measured.²³ Baseline creatine kinase (CK) measurement is recommended only if the patient presents with persistent, generalised, unexplained muscle symptoms before starting treatment.³⁹
• Follow-up Timing for Efficacy: NICE NG238 recommends repeating the full lipid profile 2 to 3 months after initiating or changing any lipid-lowering therapy to assess the patient’s response.⁶ This allows determination of whether the treatment target (e.g., >40% non-HDL-C reduction in primary prevention) has been achieved.
• Frequency of Monitoring:

• Lipids: After the initial 2-3 month check, NICE suggests considering an annual full lipid profile measurement for patients on treatment for primary prevention.²⁸ This serves to inform ongoing discussions about treatment effectiveness, medication adherence, and lifestyle factors.²⁸ For secondary prevention, where absolute targets apply, monitoring might need to be more frequent until targets are achieved, followed potentially by annual checks.²⁸ For inclisiran, due to its long-acting nature, routine lipid monitoring between the 6-monthly doses is not mandated by the NICE TA or product license, although an annual cardiovascular review remains standard practice.⁴⁵
• Liver Function Tests (LFTs): For patients initiated on statins, NICE recommends measuring LFTs within 3 months of starting treatment and again at 12 months.³⁹ Further LFT monitoring is generally not required unless clinically indicated (e.g., symptoms suggestive of liver dysfunction).³⁹ Similar monitoring (baseline and 3 months) may be prudent when ezetimibe is co-administered with a statin.⁵⁸ Bempedoic acid has also been associated with LFT elevations, suggesting baseline and follow-up monitoring may be warranted.⁶⁹ If transaminase levels rise to more than 3 times the upper limit of normal (>3x ULN), the statin (or potentially other agent) should usually be discontinued and LFTs rechecked.²⁸
• Creatine Kinase (CK): Routine monitoring of CK levels in asymptomatic patients receiving lipid-lowering therapy (including statins) is not recommended by NICE.³⁹ CK should only be measured if a patient develops unexplained muscle symptoms (pain, tenderness, or weakness) while on treatment.³⁹
• Assessing Response and Action: Monitoring results should be interpreted in the context of the treatment goals. For primary prevention, the key assessment at 2-3 months is whether a >40% reduction in non-HDL-C has been achieved.⁶ If the target is not met, the clinician should discuss potential reasons with the patient, including medication adherence, timing of dose administration, and reinforcement of diet and lifestyle advice.²³ If adherence and lifestyle are optimised but the target remains unmet, intensification of therapy according to the appropriate NICE pathway (e.g., increasing statin dose if tolerated, or moving to the next step in the statin intolerance pathway) should be considered.²³

9. Conclusion

Managing cardiovascular risk in a 50-year-old, statin-intolerant patient with significantly elevated lipids (non-HDL-C 5.9 mmol/L, LDL-C 4.6 mmol/L, TG 3.0 mmol/L) requires a structured approach guided by UK NICE recommendations. The process begins with a formal 10-year CVD risk assessment using QRISK3, supplemented by interpretation of the full lipid profile. Given the lipid levels, this patient is highly likely to exceed the 10% QRISK3 threshold, indicating a need for pharmacological intervention alongside comprehensive lifestyle modifications.

The primary therapeutic goal in this primary prevention scenario is to achieve a greater than 40% reduction in non-HDL cholesterol from baseline. Due to confirmed statin intolerance, the NICE-recommended pathway involves initiating ezetimibe monotherapy. If the non-HDL-C target is not met, the next step involves the fixed-dose combination of bempedoic acid and ezetimibe, contingent on the NHS commercial arrangement.

Access to more potent injectable therapies (PCSK9 inhibitors, inclisiran) for primary prevention is currently restricted by NICE due to cost-effectiveness considerations, generally being reserved for patients with specific high-risk conditions like severe HeFH or for use within research settings. This creates a potential treatment gap for high-risk statin-intolerant individuals whose lipids may not be adequately controlled with available oral therapies. Therefore, careful monitoring of response, ongoing emphasis on lifestyle factors, and potentially specialist consultation are crucial for optimising management in such cases. Individualized care, considering patient preferences, comorbidities, and the evolving evidence base, remains paramount.

10. Disclaimer

This report provides information based on current UK clinical guidelines (NICE) and published research evidence. It is intended for informational purposes for healthcare professionals and researchers and does not constitute medical advice. Individual patient diagnosis and treatment decisions must be made by a qualified healthcare provider in consultation with the patient, considering their full clinical context and preferences.

Works cited

1. Statin Intolerance Pathway, accessed April 9, 2025, https://www.nottsapc.nhs.uk/media/1702/statin-intolerance-pathway.pdf
2. www.nice.org.uk, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta385/documents/final-appraisal-determination-document
3. NPC Archive Item: Ezetimibe in hypercholesterolaemia: NICE guidance, accessed April 9, 2025, https://www.centreformedicinesoptimisation.co.uk/ezetimibe%E2%96%BC-in-hypercholesterolaemia-nice-guidance/
4. REVIEW Statin Intolerance: A Mini Review Rana Zhafira Amanda,1 Natasha Anindhia Harsas,2 Sidhi Laksono Purwowiyoto2,3 Keywords:, accessed April 9, 2025, https://medicine.missouri.edu/sites/default/files/ajhm/Statin_Intolerance-A_Mini_Review.pdf
5. Referral criteria – intolerant to statins (statin intolerance) – GPnotebook, accessed April 9, 2025, https://gpnotebook.com/en-GB/pages/cardiovascular-medicine/referral-criteria-intolerant-to-statins-statin-intolerance
6. Cardiovascular disease — risk assessment and reduction: NICE 2023 update for GPs, accessed April 9, 2025, https://bjgp.org/content/74/748/523
7. Overview | Cardiovascular disease: risk assessment and reduction …, accessed April 9, 2025, https://www.nice.org.uk/guidance/ng238
8. Cardiovascular disease: risk assessment and reduction, including lipid modification – NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/cg181
9. Summary of national guidance for lipid management – NHS England, accessed April 9, 2025, https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/
10. The Heart of the Matter (Part 2): NICE Guidelines on CVD risk reduction and Lipid Management – YouTube, accessed April 9, 2025, https://www.youtube.com/watch?v=QyN3toBGCNU
11. Cardiovascular Risk Assessment | Doctor – Patient.info, accessed April 9, 2025, https://patient.info/doctor/cardiovascular-risk-assessment
12. Cardiovascular risk assessment and lipid modification: NICE guideline – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4484941/
13. Quality statement 1: Full formal risk assessment using QRISK3 | Cardiovascular risk assessment and lipid modification – NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/qs100/chapter/Quality-statement-1-Full-formal-risk-assessment-using-QRISK3
14. QRISK3, accessed April 9, 2025, https://qrisk.org/
15. Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus – Frontiers, accessed April 9, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1077632/full
16. Cardiovascular Risk Score (QRISK3) Patient Information Leaflet – Hornchurch Healthcare, accessed April 9, 2025, https://www.hornchurchhealthcare.co.uk/appointmentstest-referrals/tests-investigations/cardiovascular-risk-score-qrisk3-patient-information-leaflet/
17. Welcome to the QRISK ® -lifetime cardiovascular risk calculator, accessed April 9, 2025, https://www.qrisk.org/lifetime/
18. Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10646868/
19. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study | The BMJ, accessed April 9, 2025, https://www.bmj.com/content/357/bmj.j2099
20. www.nice.org.uk, accessed April 9, 2025, https://www.nice.org.uk/guidance/ng238/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-66143902851781
21. Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank – PubMed, accessed April 9, 2025, https://pubmed.ncbi.nlm.nih.gov/37423742/
22. Lipid Management for the Primary and Secondary Prevention of Cardiovascular Disease – Kidney Research UK, accessed April 9, 2025, https://www.kidneyresearchuk.org/wp-content/uploads/2025/02/Lipids_Primary_Care_Hack_v8_Feb_25.pdf
23. South West London Integrated Care System Lipid Management Guidance: Adult Medicines Optimisation pathways, accessed April 9, 2025, https://swlimo.southwestlondon.icb.nhs.uk/wp-content/uploads/SWL-Lipid-management-guidelines-for-adults-V2.0.pdf?UNLID=1040849582025215165327
24. Briefing note: The role of inclisiran in lipid management – NHS England, accessed April 9, 2025, https://www.england.nhs.uk/long-read/briefing-note-the-role-of-inclisiran-in-lipid-management/
25. Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10219398/
26. The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4719137/
27. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD, accessed April 9, 2025, https://www.nottsapc.nhs.uk/media/0aod5fib/final-hyperlipidaemia-guidelines.pdf
28. Q&A: Lipid management – Part 2: Use of statins – DiabetesontheNet, accessed April 9, 2025, https://diabetesonthenet.com/diabetes-primary-care/qa-lipid-management-part-2-use-of-statins/
29. Cardiovascular disease: risk assessment and reduction, including lipid modification | Guidance | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ng238/chapter/Recommendations
30. NICE and SMC Guidance Praluent® (alirocumab) – Sanofi campus, accessed April 9, 2025, https://pro.campus.sanofi/uk/dyslipidaemia/articles/nice-and-smc-guidance-praluent
31. 4 Consideration of the evidence | Evolocumab for treating primary …, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta394/chapter/4-consideration-of-the-evidence
32. Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders – PubMed Central, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11865805/
33. Cardiovascular Health Risk Assessment – Patient.info, accessed April 9, 2025, https://patient.info/heart-health/cardiovascular-disease-atheroma/cardiovascular-health-risk-assessment
34. Lipids module 4: treatment of dyslipidaemia – The British Journal of Cardiology, accessed April 9, 2025, https://bjcardio.co.uk/2024/06/lipids-module-4-treatment-of-dyslipidaemia-5/
35. Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors | ECR Journal, accessed April 9, 2025, https://www.ecrjournal.com/articles/management-severe-dyslipidaemia-role-pcsk9-inhibitors?language_content_entity=en
36. Q&A: Lipid management – Part 2: Use of statins | DiabetesontheNet, accessed April 9, 2025, https://diabetesonthenet.com/wp-content/uploads/91.-QA-Lipids-pt2-statins.pdf
37. Lipid-lowering therapies for the secondary prevention of cardiovascular disease in primary care – The Pharmaceutical Journal, accessed April 9, 2025, https://pharmaceutical-journal.com/article/ld/lipid-lowering-therapies-for-the-secondary-prevention-of-cardiovascular-disease-in-primary-care
38. Diagnosis and Management of Statin Intolerance – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6402887/
39. Lipid management: Insights from NICE clinical guidelines 2023, accessed April 9, 2025, https://hvt-journal.com/articles/art476
40. Welcome to ACC’s Statin Intolerance Tool – Mobile and Web Apps – American College of Cardiology, accessed April 9, 2025, https://tools.acc.org/statinintolerance/
41. Ezetimibe for treating primary heterozygous- familial and non-familial hypercholesterolaemia | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta385/resources/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia-pdf-82602851386309
42. www.nice.org.uk, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta694/documents/final-appraisal-determination-document
43. 3 Committee discussion | Inclisiran for treating primary … – NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta733/chapter/3-Committee-discussion
44. NICE TA implementation guidance – Alirocumab and evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia – East Kent Prescribing Formulary, accessed April 9, 2025, https://www.eastkentformulary.nhs.uk/media/1138/ekpg-recommendation-evolocumab-and-alirocumab-for-hypercholesterolaemia.pdf
45. Inclisiran Information for Healthcare Professionals Quick Reference Guide 03.07.23.docx, accessed April 9, 2025, https://surreyccg.res-systems.net/PADFormularyV1/Content/Documents/2/Final%20Inclisiran%20Information%20for%20Healthcare%20Professionals%20Quick%20Reference%20Guide%2003.07.23%20(007)%20(1).docx
46. 3 Evidence | Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | Guidance | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta393/chapter/3-Evidence
47. ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6047410/
48. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients – PubMed, accessed April 9, 2025, https://pubmed.ncbi.nlm.nih.gov/37354546/
49. Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention | tctmd.com, accessed April 9, 2025, https://www.tctmd.com/news/big-reductions-ascvd-events-bempedoic-acid-primary-prevention
50. Bempedoic acid (monotherapy) or bempedoic acid in combination with ezetimibe for primary hypercholesterolaemia or mixed dyslipidaemia – NIHR Innovation Observatory, accessed April 9, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/12682-Bempedoic-acid-with-or-without-ezetimibe-for-hypercholesterolaemia-V1.0-SEP2018-NONCONF.pdf
51. Perspectives in Cholesterol-Lowering Therapy – American Heart Association Journals, accessed April 9, 2025, https://www.ahajournals.org/doi/10.1161/01.cir.0000072345.98581.24
52. Ezetimibe – An Overview of its Low-density Lipoprotein Cholesterol Lowering Efficacy, accessed April 9, 2025, https://www.ecrjournal.com/articles/ezetimibe-overview-its-low-density-lipoprotein-cholesterol-lowering-efficacy?language_content_entity=en
53. Ezetimibe: The Lower the LDL-C, the Better (Even for Total Cardiovascular Events), accessed April 9, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2016/03/09/06/50/Ezetimibe-The-Lower-the-LDLC-the-Better
54. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor, accessed April 9, 2025, https://academic.oup.com/eurheartjsupp/article-pdf/3/suppl_E/E11/9795884/E11.pdf
55. Ezetimibe – an update | Drug and Therapeutics Bulletin, accessed April 9, 2025, https://dtb.bmj.com/content/47/8/91
56. Side effects of ezetimibe – NHS, accessed April 9, 2025, https://www.nhs.uk/medicines/ezetimibe/side-effects-of-ezetimibe/
57. Ezetimibe 10 mg Tablets – Summary of Product Characteristics (SmPC) – (emc) | 9135, accessed April 9, 2025, https://www.medicines.org.uk/emc/product/9135/smpc
58. Ezetimibe 10 mg tablets – Summary of Product Characteristics (SmPC) – (emc) | 9278, accessed April 9, 2025, https://www.medicines.org.uk/emc/product/9278/smpc
59. Ezetimibe Tablets – Accord Products Database, accessed April 9, 2025, https://accord-healthcare-products.co.uk/products/e/ezetimibe-tablets
60. Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11943254/
61. Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid – Business Wire, accessed April 9, 2025, https://www.businesswire.com/news/home/20240926678909/en/Final-Real-World-Results-from-MILOS-German-Cohort-Demonstrate-Strong-Increase-in-LDL-C-Goal-Achievement-With-Addition-of-Bempedoic-Acid
62. Nilemdo 180mg film-coated tablets – Summary of Product Characteristics (SmPC) – (emc), accessed April 9, 2025, https://www.medicines.org.uk/emc/product/11743/smpc
63. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin …, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2024.04.048
64. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin …, accessed April 9, 2025, https://pubmed.ncbi.nlm.nih.gov/38960508/
65. Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention – PubMed Central, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10900064/
66. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance | Journal of the American Heart Association, accessed April 9, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.118.011662
67. Bempedoic acid has similar CV benefits as statins when normalized …, accessed April 9, 2025, https://pace-cme.org/news/bempedoic-acid-has-similar-cv-benefits-statins-when-normalized-degree-ldl-c-lowering/2468192/
68. Study Shows Bempedoic Acid Comparable to Statins in … – HCPLive, accessed April 9, 2025, https://www.hcplive.com/view/study-shows-bempedoic-acid-comparable-to-statins-in-cardiovascular-protection
69. Nustendi 180mg/10mg film-coated tablets – Summary of Product Characteristics (SmPC) – (emc) | 11744, accessed April 9, 2025, https://www.medicines.org.uk/emc/product/11744/smpc
70. amber-G guideline – Barnsley Area Prescribing Committee, accessed April 9, 2025, https://best.barnsleyccg.nhs.uk/clinical-support/medicines/shared-care-guidelines/Bempedoic%20Acid%20Amber-G%20Guidance.pdf
71. Bempedoic Acid – StatPearls – NCBI Bookshelf, accessed April 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK594232/
72. Bempedoic acid (oral route) – Mayo Clinic, accessed April 9, 2025, https://www.mayoclinic.org/drugs-supplements/bempedoic-acid-oral-route/description/drg-20484223
73. Bempedoic acid: Uses, Dosage, Side Effects, Warnings – Drugs.com, accessed April 9, 2025, https://www.drugs.com/bempedoic-acid.html
74. NICE sets out draft recommendations for evolocumab in Final Appraisal Determination, accessed April 9, 2025, https://hospitalpharmacyeurope.com/clinical-zones/cardiovascular-medicine/nice-sets-out-draft-recommendations-for-repatha-evolocumab-in-final-appraisal-determination/
75. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial – JACC Journals, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499
76. Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain – Revista Española de Cardiología, accessed April 9, 2025, https://www.revespcardiol.org/en-cost-effectiveness-and-budget-impact-of–articulo-S1885585718301877
77. Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy | Povero | Farmeconomia. Health economics and therapeutic pathways, accessed April 9, 2025, https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1499/1879
78. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | NICE, accessed April 9, 2025, https://www.nice.org.uk/guidance/ta393/resources/alirocumab-for-treatingprimary-hypercholesterolaemia-and-mixeddyslipidaemia-pdf-82602908493253
79. Repatha SureClick – Summary of Product Characteristics (SmPC) – (emc) | 6962, accessed April 9, 2025, https://www.medicines.org.uk/emc/product/6962/smpc
80. Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience – PMC, accessed April 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6704355/
81. First PCSK9 inhibitors approved in Europe and United States – The Pharmaceutical Journal, accessed April 9, 2025, https://pharmaceutical-journal.com/article/news/first-pcsk9-inhibitors-approved-in-europe-and-united-states
82. Leqvio | European Medicines Agency (EMA), accessed April 9, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
83. Amber Guidance for Inclisiran for treating Primary Hypercholesterolaemia or Mixed Dyslipidaemia, accessed April 9, 2025, https://www.northernlincolnshireapc.nhs.uk/wp-content/uploads/2022/10/Amber-1-Inclisiran-guideline-10.22.pdf
84. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials, accessed April 9, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2023.10.007
85. New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender, accessed April 9, 2025, https://www.novartis.com/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender
86. Efficacy & Clinical Trials | LEQVIO® (inclisiran) | HCP, accessed April 9, 2025, https://www.leqviohcp.com/efficacy
87. Leqvio 284 mg solution for injection in pre filled syringe – Summary of Product Characteristics (SmPC) – (emc) | 12039, accessed April 9, 2025, https://www.medicines.org.uk/emc/product/12039/smpc
88. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial | Cardiovascular Research | Oxford Academic, accessed April 9, 2025, https://academic.oup.com/cardiovascres/article/120/12/1400/7675310
89. Leqvio, INN-inclisiran, accessed April 9, 2025, https://www.medicines.org.uk/emc/files/pil.12039.pdf
90. Prescribing Support Guide Inclisiran (Leqvio®) for treating primary hypercholesterolaemia or mixed dyslipidaemia, accessed April 9, 2025, https://www.hweclinicalguidance.nhs.uk/all-clinical-areas-documents/download?cid=2497&checksum=d9fc0cdb67638d50f411432d0d41d0ba
91. Inclisiran Side Effects: Common, Severe, Long Term – Drugs.com, accessed April 9, 2025, https://www.drugs.com/sfx/inclisiran-side-effects.html

Statins monitoring – SPS – Specialist Pharmacy Service – The first stop for professional medicines advice, accessed April 9, 2025, https://www.sps.nhs.uk/monitorings/statins-monitoring/